May 24, 2022
MediSieve Receives Approval for First-in-Man Clinical Investigation
Radboud University Medical Center will perform the first trial of the Novel Magnetic Haemoflitration System.
LONDON, UK, May. 24, 2022 – MediSieve, a biotech startup focused on developing novel blood filtration therapies, today reported that it has received approval to perform a first-in-man (FIM) clinical investigation of its Magnetic Haemofiltration System in the Netherlands.
The study is set to begin in June of 2022 at the Radboud University Medical Center, a leading Dutch medical research institution. Prof. Peter Pickkers and Dr. Matthijs Kox, both world experts in FIM trials, are leading the study. Prof. Pickkers’ research focuses on pharmacological modulation of the innate immune response, and he is the Head of Research at the Radboud UMC.
The clinical investigation announced by MediSieve is a fundamental moment for the company. MediSieve’s Founder and CEO, Dr. George Frodsham, said:
“This is a huge step for us as a company – this is the first time our products are going to be used in humans. We couldn’t be working with a better clinical team than the one at Radboud, and we are very excited to see the results. This study will bring us one step closer to getting our product – the first, we hope, of many for our platform – approved for use in hospitals around the world.”
MediSieve’s pivotal IL-6 product is designed to treat acute cases of IL-6-driven hyperinflammation in patients with Cytokine storms, AKI, ARDS, CRS, Pancreatitis, Cardiac Surgery and others. Patients with elevated IL-6 levels have high mortality and morbidity rates and put a significant worldwide burden on healthcare systems. Currently, the most common treatment is systemic IL-6 inhibitors. However, these drugs are unsuitable for the treatment of acute hyperinflammation because they cause long-term immunosuppression that leaves patients more vulnerable to both the initial and newly acquired infections.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
